331. Idiopathic multicentric castleman disease Clinical trials / Disease details
Clinical trials : 33 / Drugs : 46 - (DrugBank : 25) / Drug target genes : 31 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04743687 (ClinicalTrials.gov) | January 1, 2021 | 3/2/2021 | Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm Trial | The Efficacy and Safety of Zanuburutinib in Relapsed and Refractory Idiopathic Multicentric Castleman Disease (iMCD): a Prospective, Single-center, Single-arm Trial | Idiopathic Multicentric Castleman's Disease | Drug: Zanubrutinib | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | China |